TiGenix completes third and final phase of the Orthomimetics acquisition

In November 2009, TiGenix acquired all the shares in Orthomimetics Limited (currently TiGenix Limited) through a share deal. The consideration due by TiGenix was payable in TiGenix shares, a first tranche of which was issued in November 2009, a second tranche in November 2010 and a third and final tranche today.

At the occasion of today's issue of shares, 536,534 new TiGenix shares were issued. The registered capital of the company was increased with EUR 525,803.32 and an issuance premium of EUR 1,770,561.44 was recorded.

The 536,534 new TiGenix shares will be admitted to trading on NYSE Euronext Brussels. Following this transaction, the total number of shares outstanding is 91,659,201.

For more information:

Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com    

Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com                   

Hans Herklots
Director Investor & Media Relations
hans.herklots@tigenix.com
+32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with one marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.